Citius Pharmaceuticals Inc (CTXR)

NASDAQ
1.940
-0.090(-4.43%)
After Hours
1.950
+0.010(+0.515%)
- Real-time Data
  • Volume:
    7,025,610
  • Bid/Ask:
    1.940/1.950
  • Day's Range:
    1.860 - 2.000

CTXR Overview

Prev. Close
2.03
Day's Range
1.86-2
Revenue
-
Open
1.99
52 wk Range
0.873-4.55
EPS
-0.32
Volume
7,025,610
Market Cap
283.2M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,647,253
P/E Ratio
-
Beta
1.48
1-Year Change
76.36%
Shares Outstanding
145,979,429
Next Earnings Date
Mar 02, 2022
What is your sentiment on Citius Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Citius Pharmaceuticals Inc News

Citius Pharmaceuticals Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellStrong SellSell
Technical IndicatorsSellStrong SellStrong SellStrong SellNeutral
SummarySellStrong SellStrong SellStrong SellNeutral

Citius Pharmaceuticals Inc Company Profile

Citius Pharmaceuticals Inc Company Profile

Employees
10

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products targeting medical needs with a focus on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing four proprietary products, including Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Read More
  • I just jumped in today !
    1
    • long term lotto ffhl
      2
      • russel 2000 and phase 3 results next week, even if we see a correction today i'm not slightly worried. long on citius, i've done some deep DD and i am leaving my money in there for a good year at the very least
        2
        • I need more time for my transanction then buy more stuff. Long term is incredible due to great stock.
          0
      • Nice bounce back, hopefully no one sold the dip in panic
        0
        • Just regular correction for long day bullish stock, I guess it gonna back on track for sure.
          0
          • To quote a value investing mastermind, I like the stock
            0
            • sorry guys. just bought in. that's why it sunk on you. my bad.
              0
              • a part, the message with "to the Moon", someone want to start a discussion about some estimate about the next value of CTXR, with concrete informations?
                0
                • to mars🚀
                  0
                • Some of you guys are funny. You demand trustworthy DD for free from user of free stocks platform…
                  1
              • Coming soon, I am sure this stock will go to the moon.
                0
                • https://seekingalpha.com/pr/18243773-sellas-life-sciences-reports-full-year-2020-financial-results-and-provides-business-update
                  0
                  • This unkown high potentential stock just discovery.!!!
                    0
                    • Up up away it goes! Finally getting the regognition for their efforts.
                      0
                      • what happened massimocular
                        0
                        • len
                          0
                      • Also, very important information is that the interim data analysis for the study has been lowered from 75% to 65% because of the fast track and success rate of the study in previous trials. This means the study will be evaluated at 65% completion, and depending on the results - the study could be considered successful ahead of schedule.
                        0
                        • In a Phase 2b trial, Mino-Lok demonstrated a 100% efficacy rate in salvaging colonized CVCs. Mino-Lok is currently in a Phase 3 pivotal superiority trial.  To The Moon!
                          0
                          • https://twitter.com/CitiusPharma/status/1364954829899104268
                            0
                            • i have bad news. i bought this stock and it will be red forever.
                              0
                              • a broken clock is right twice a day - this may be your lucky one :)
                                0
                            • what are we expecting over next 2 weeks 3.5? predictions seem all over the place.
                              0
                              • 4 min 6 max 💪
                                0
                            • News out today on CTXR, take a look here:  https://www.barchart.com/story/stocks/quotes/CTXR/news/1187185/extensive-demand-for-t-cell-adoptive-immunotherapy-rising-with-growing-prevalence-of-cancer
                              0
                              • Hi! The article may be of today, but the shareholder update mentioned is of Feb 16. So it's not new information.
                                0
                            • Just hold on later this week we might get industrial investors buying CTXR then price improvements. Hold for now.
                              0
                              • The whole market dropped
                                0
                                • CTXR had almost 10% gain today
                                  0
                              • why is it dropping?
                                1
                                • What do you mean? Last close on Friday was 2.06 - on a bad day, this will still finish in the green
                                  0
                              • will it continue to grow?
                                0
                                • why?
                                  0
                                  • 3$ PT for today!
                                    0
                                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.